Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association. (16th October 2018)

• Record Type: Journal Article
• Authors: Morse, Elliot; Berson, Elisa; Fujiwara, Rance; Judson, Benjamin; Mehra, Saral
• Is Part Of: Otolaryngology--head and neck surgery. Volume 160:Number 2(2019)
• Page Start: 267
• Page End: 276
• Publication Date: 2018-10-16
• Subjects: head and neck cancer -- hypopharyngeal cancer -- treatment delays -- quality indicators -- radiation -- surgery; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0194599818797605
• Languages: English
• ISSNs: 0194-5998

Abstract

Abstract : Objective: To characterize treatment delays in hypopharyngeal cancer, identify factors associated with delays, and associate delays with overall survival. Study Design: Retrospective cohort. Setting: Commission on Cancer hospitals nationwide. Subjects and Methods: We included patients in the National Cancer Database who were treated for hypopharyngeal cancer with primary radiation, concurrent chemoradiation, or induction chemotherapy and radiation. We identified median durations of diagnosis to treatment initiation (DTI), radiation treatment duration (RTD), and diagnosis to treatment end (DTE). We associated delays with patient, tumor, and treatment factors and overall survival via multivariable logistic and Cox proportional hazards regression, respectively. Results: A total of 3850 patients treated with primary radiation or concurrent chemoradiation were included. Median durations of DTI, RTD, and DTE were 37, 52, and 92 days, respectively. Nonwhite race was associated with delays in DTI (odds ratio [OR] = 0.64; 95% CI, 0.51‐0.80; P <. 001) and DTE (OR = 0.60; 95% CI, 0.49‐0.75; P <. 001). Medicaid insurance was associated with delays in DTI (OR = 1.43; 95% CI, 1.07‐1.90; P =. 015), RTD (OR = 1.39; 95% CI, 1.06‐1.83; P =. 018), and DTE (OR = 1.48; 95% CI, 1.12‐1.97; P =. 007). Delays in RTD (hazard ratio [HR] = 1.24; 95% CI, 1.11‐1.37; P <. 001), not DTI (HR = 0.92; 95% CI, 0.82‐1.03; P =. 150) or DTE (HR = 1.01; 95% CI, 0.90‐1.15; P =. 825), were associated with impaired overall survival. We identified 922 patients who received induction chemotherapy. Delays in DTI, RTD, and DTE were not associated with overall survival in this cohort (HR = 1.10; 95% CI, 0.87‐1.39; P = 0.435; HR = 1.05; 95% CI, 0.83‐1.32; P = 0.686; HR = 1.11; 95% CI, 0.88‐1.41; P = 0.377, respectively). Conclusions: The median durations identified can serve as national benchmarks. Delays during radiation are associated with impaired overall survival among patients treated with primary radiation or chemoradiation but not patients treated with induction chemotherapy.